NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Forecast, Price & News

$0.23

-0.01 (-4.22%)

(As of 05/26/2023 ET)

Compare

Today's Range: $0.21
▼
$0.24
50-Day Range: $0.19
▼
$0.24
52-Week Range: $0.13
▼
$2.10

Volume: 322,369 shs
Average Volume: 358,858 shs
Market Capitalization: $6.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Benitec Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,664.4% Upside
$4.00 Price Target
Short Interest: Healthy
1.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Benitec Biopharma has a forecasted upside of 1,664.4% from its current price of $0.23.
Amount of Analyst Coverage
Benitec Biopharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.13% of the outstanding shares of Benitec Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Benitec Biopharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Benitec Biopharma has recently decreased by 5.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Benitec Biopharma does not currently pay a dividend.
Dividend Growth
Benitec Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNTC.

3.0

News and Social Media Coverage

News Sentiment
Benitec Biopharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Benitec Biopharma this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.57% of the stock of Benitec Biopharma is held by insiders.
Percentage Held by Institutions
69.70% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Benitec Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Benitec Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Benitec Biopharma has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Stock News Headlines

May 18, 2023 | msn.com

JMP Securities Reiterates Benitec Biopharma (BNTC) Market Outperform Recommendation

May 18, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on Benitec Biopharma (BNTC)

May 28, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>

May 17, 2023 | americanbankingnews.com

Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results

May 16, 2023 | marketwatch.com

8-K: Benitec Biopharma Inc.

May 15, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 15, 2023 | finance.yahoo.com

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 8, 2023 | finance.yahoo.com

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

May 28, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

April 27, 2023 | americanbankingnews.com

Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 73.4% in April

April 17, 2023 | americanbankingnews.com

Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

April 14, 2023 | nbcnews.com

More than 200 drugmakers led by Pfizer blast Texas judge's abortion pill decision

March 1, 2023 | seekingalpha.com

BNTC Benitec Biopharma Inc.

February 13, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

February 13, 2023 | finance.yahoo.com

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

January 23, 2023 | finance.yahoo.com

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

January 13, 2023 | finance.yahoo.com

Biopharma Giants Gather at JPMorgan Conference After ‘Depressing’ Year

November 10, 2022 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

November 10, 2022 | finance.yahoo.com

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

September 16, 2022 | finance.yahoo.com

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

September 13, 2022 | finance.yahoo.com

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

August 25, 2022 | finance.yahoo.com

Benitec Biopharma Inc. (BNTC)

July 15, 2022 | finance.yahoo.com

Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected

June 24, 2022 | marketwatch.com

Benitec Biopharma Shares Surge 119%, to $1.62

May 16, 2022 | finance.yahoo.com

Benitec Biopharma Releases Q3 2022 Financial Results

February 14, 2022 | finance.yahoo.com

Benitec Biopharma Discloses Q2 2022 Financial Results

January 18, 2022 | finance.yahoo.com

/C O R R E C T I O N from Source -- Norra Metals Corp./

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Company Calendar

Last Earnings: 5/15/2023
Today: 5/28/2023
Fiscal Year End: 6/30/2023
Next Earnings (Estimated): 9/01/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BNTC
CUSIP: N/A
CIK: 1808898
Web: www.benitec.com
Phone: 510-780-0819
Fax: 61 (0)3 9966-9923
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +1,664.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($41.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,210,000.00
Net Margins: N/A
Pretax Margin: -29,364.70%
Return on Equity: -255.98%
Return on Assets: -180.65%

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 2.35
Quick Ratio: 2.35

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 90.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 1.33

Miscellaneous

Outstanding Shares: 27,980,000
Free Float: 27,542,000
Market Cap: $6.34 million
Optionable: Not Optionable
Beta: 1.15

Key Executives

Dr. Jerel A. Banks M.D. (Age 48)
Ph.D., Exec. Chairman & CEO
Comp: $539.96k

Ms. Megan Joan Boston BComm (Age 51)
CA, Dip., GAICD, Exec. Director
Comp: $329.46k

Mr. Bryan Dulhunty
Chief Financial Officer

Dr. Michael Graham
Head of Discovery & Founding Scientist

Dr. Craig Lewis
Chief Medical Adviser

Dr. Claudia Kloth
Sr. VP of Manufacturing

Key Competitors

View All Competitors

Institutional Ownership

Renaissance Technologies LLC
Sold 150,652 shares on 5/12/2023
Ownership: 0.804%

View All Institutional Transactions

BNTC Stock - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings or view top-rated stocks.
What is Benitec Biopharma's stock price forecast for 2023?: 2 Wall Street analysts have issued 12-month price targets for Benitec Biopharma's stock. Their BNTC share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,664.4% from the stock's current price.
View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts.
How have BNTC shares performed in 2023?: Benitec Biopharma's stock was trading at $0.17 at the beginning of 2023. Since then, BNTC shares have increased by 33.4% and is now trading at $0.2267.
View the best growth stocks for 2023 here.
Are investors shorting Benitec Biopharma?: Benitec Biopharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 317,400 shares, a decrease of 5.8% from the April 30th total of 337,000 shares. Based on an average daily trading volume, of 298,000 shares, the days-to-cover ratio is currently 1.1 days.
View Benitec Biopharma's Short Interest.
When is Benitec Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, September 1st 2023.
View our BNTC earnings forecast.
How were Benitec Biopharma's earnings last quarter?: Benitec Biopharma Inc. (NASDAQ:BNTC) announced its quarterly earnings results on Monday, May, 15th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter. The biotechnology company earned $0.05 million during the quarter.

What other stocks do shareholders of Benitec Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).
When did Benitec Biopharma IPO?: (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.
What is Benitec Biopharma's stock symbol?: Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."
Who are Benitec Biopharma's major shareholders?: Benitec Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.80%).
View institutional ownership trends.
How do I buy shares of Benitec Biopharma?: Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Benitec Biopharma's stock price today?: One share of BNTC stock can currently be purchased for approximately $0.23.
How much money does Benitec Biopharma make?: Benitec Biopharma (NASDAQ:BNTC) has a market capitalization of $6.34 million and generates $70,000.00 in revenue each year. The biotechnology company earns $-18,210,000.00 in net income (profit) each year or ($41.25) on an earnings per share basis.
How can I contact Benitec Biopharma?: Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The official website for the company is www.benitec.com. The biotechnology company can be reached via phone at 510-780-0819, via email at jmorakis@mgroupsc.com, or via fax at 61 (0)3 9966-9923.

This page (NASDAQ:BNTC) was last updated on 5/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial